← Novo Nordisk

What podcasts say about Novo Nordisk

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about Novo Nordisk

43 statements · 22 positive · 18 negative · 1 mixed · 2 neutral

  1. Dan NathanNeutralNov 4, 2026· CNBC's "Fast Money"

    Novo Nordisk needs a stronger pipeline to advance its stock valuation.

    “it's got to be pipeline oriented, I think, to get the stock to the next level.”

    Listen at 33:35

    Open the episode · Market’s Post-Election Surge… And Prognosis For Pharma, Health Care After Midterms 11/4/26
  2. Novo Nordisk trades roughly 12 times forward earnings after falling 40% from its 52-week high.

    “that stock is down 40%. And from its 52-week high, and it's trading roughly around 12 times forward earnings.”

    Listen at 3:26

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  3. Novo Nordisk is a century-old, high-quality business.

    “it's a company that's 100 plus year old, great business.”

    Listen at 4:12

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  4. Novo Nordisk is a good business priced as if it were rapidly deteriorating.

    “good business at a price that assumes that it's a melting ice cube”

    Listen at 4:26

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  5. Novo Nordisk can deliver mid-single-digit earnings growth and a 4.5% dividend without another blockbuster.

    “my assumption is base case is even in a mediocre scenario, if they can't come up with another blockbuster, the earnings are in the mid single digits. And then we get a dividend of 4.5% to wait.”

    Listen at 8:27

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  6. Novo Nordisk could return 18% to 22% if its new drugs succeed.

    “The returns can be in the upwards of 18% to 22%”

    Listen at 11:37

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  7. Novo Nordisk could produce strong returns if Amicretin succeeds, otherwise returns may be 8–9%.

    “I'm expecting really good returns if they're able to be successful with Omicretin. And that's the risk here. Else, you have to be satisfied with a mediocre return of 8% to 9%.”

    Listen at 20:58

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  8. Most negative news about Novo Nordisk is already reflected in its valuation.

    “My thesis here is most of the bad news is baked in.”

    Listen at 21:32

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  9. Novo Nordisk’s valuation could improve if its pipeline produces successful drugs by 2028–2030.

    “if they're able to get out with some good drugs, including Amicretin and others that they have by 28, 29, 30, then the valuation will also change accordingly.”

    Listen at 22:01

    Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra
  10. John FlavinPositiveOct 5, 2026· CNBC's "Fast Money"

    Novo Nordisk retains long-term value despite current investor impatience.

    “Looking over the longer term, I still believe that Novo has value”

    Listen at 32:33

    Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26
  11. John FlavinPositiveOct 5, 2026· CNBC's "Fast Money"

    Long-term holders of Novo Nordisk are likely to be rewarded.

    “hold for a long time and likely you'll be rewarded”

    Listen at 33:28

    Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26
  12. Louise MoonNegativeSep 25, 2026· Stock Movers

    The Nanexa deal is unlikely to trigger Novo Nordisk’s price in the short term.

    “it's unlikely to be a short-term trigger for their price”

    Listen at 2:53

    Open the episode · UBS Rises, Novo Climbs, HelloFresh Plummets
  13. Alexis ChristoforousNegativeSep 21, 2026· Stock Movers

    Novo Nordisk disappointed investors with its turnaround plans.

    “Novo Nordisk. Disappointing investors here.”

    Listen at 2:22

    Open the episode · Novo Slides; Accenture Up; Arhaus Upgrade
  14. Alexis ChristoforousNegativeSep 21, 2026· Stock Movers

    Novo Nordisk quickly lost its GLP-1 market lead to Eli Lilly.

    “it quickly lost its lead. to Eli Lilly.”

    Listen at 2:31

    Open the episode · Novo Slides; Accenture Up; Arhaus Upgrade
  15. Novo Nordisk’s stock is approximately back to its pre-Wegovy level.

    “If you look at Novo Nordistock, I think it's about where it was before Wiggovi came to the market”

    Listen at 18:50

    Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
  16. Chloe MelleyNegativeSep 11, 2026· Stock Movers

    Loss of exclusivity will challenge Novo Nordisk

    “this loss of exclusivity on some of those drugs is going to be a huge challenge for Novo Nordisk”

    Listen at 1:12

    Open the episode · Novo Nordisk Drops, Puma Down, Trainline Rises
  17. Rachel EvansNegativeSep 11, 2026· Stock Movers

    Novo Nordisk lost obesity-drug leadership to Eli Lilly

    “They lost their leadership in the obesity drug race to Eli Lilly.”

    Listen at 1:14

    Open the episode · Novo Nordisk Drops, Berkeley Falls
  18. Chloe MelleyNegativeSep 11, 2026· Stock Movers

    Novo Nordisk’s weight-loss pill missed expectations

    “The weight loss pill did not manage to beat expectations.”

    Listen at 1:43

    Open the episode · Novo Nordisk Drops, Puma Down, Trainline Rises
  19. Jim CramerPositiveAug 12, 2026· Mad Money w/ Jim Cramer

    Novo Nordisk’s obesity and diabetes businesses are highly profitable.

    “their obesity and diabetes businesses are now printing money.”

    Listen at 11:08

    Open the episode · Mad Money w/ Jim Cramer 8/12/26
  20. Novo Nordisk has 70% more U.S. product users than roughly one year earlier

    “we have 70% more people in the U.S. using our products”

    Listen at 12:14

    Open the episode · Mad Money w/ Jim Cramer 8/12/26
  21. Novo Nordisk’s pill launch is the best pharmaceutical launch ever

    “this makes this launch the best product launch in the history of pharmaceuticals.”

    Listen at 12:48

    Open the episode · Mad Money w/ Jim Cramer 8/12/26
  22. Sustained results could turn Novo Nordisk’s recent performance into a trend

    “continue the results like we have shown in the last two quarters over a period of time, and then this moment turns into a trend”

    Listen at 20:35

    Open the episode · Mad Money w/ Jim Cramer 8/12/26
  23. Caroline HepkerNegativeAug 5, 2026· Stock Movers

    Several factors may complicate Novo Nordisk’s outlook.

    “there's going to be some, perhaps some things kind of complicating the outlook for Novo”

    Listen at 1:42

    Open the episode · Novo Nordisk Drops, Next Jumps, Infineon Falls
  24. Caroline HepkerNegativeAug 5, 2026· Stock Movers

    Novo Nordisk has experienced recent clinical-trial setbacks.

    “there's been recent trial setbacks as well for Novo”

    Listen at 2:07

    Open the episode · Novo Nordisk Drops, Next Jumps, Infineon Falls
  25. Tatiana DariaNegativeJul 31, 2026· Stock Movers

    Novo Nordisk’s experimental drug failed to reduce cardiovascular risk in a large study.

    “one of its experimental drugs failed to reduce the risk of heart disease and strokes in a large study”

    Listen at 3:01

    Open the episode · Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:
  26. Tatiana DariaNegativeJul 31, 2026· Stock Movers

    Novo Nordisk needs a new growth source because its shares have lagged since 2024.

    “the company really needs a new source of growth because shares have been lagging badly since that peak in 2024”

    Listen at 3:30

    Open the episode · Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:
  27. Tatiana DarrellNegativeJul 31, 2026· Stock Movers

    The failed drug study harms Novo Nordisk’s diversification effort beyond obesity and diabetes.

    “This is a real blow for this company as it's trying to diversify away from obesity and the diabetes space where it's been the pioneer.”

    Listen at 4:51

    Open the episode · Apple Slides Most Since 2025, Amazon Soars, Novo
  28. Clay MillayPositiveJun 19, 2026· Stock Movers

    Novo Nordisk stock is reacting positively to the foundation initiative.

    “Novo is, is reacting to that positively this morning.”

    Listen at 3:44

    Open the episode · ASML Dips, Novo Jumps, Vestas Gains
  29. Dan CurtisNegativeJun 16, 2026· Stock Movers

    Novo Nordisk’s obesity-care unit is growing at its slowest rate since 2020.

    “it's the slowest for that unit since 2020.”

    Listen at 2:55

    Open the episode · SpaceX Agrees to Merge With Cursor; Novo to File for China Approval of Wegovy; Dave & Buster's Misses Estimates
  30. Jim CramerNegativeApr 28, 2026· Mad Money w/ Jim Cramer

    Novo Nordisk is not performing well in its business.

    “I don't want your own Nova Nordisk either, though. I think that they are not good at what they do.”

    Listen at 38:48

    Open the episode · Mad Money w/ Jim Cramer 4/28/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.